Floatz logo

18f-op-801

Multiple Sclerosis (MS)

Ashvattha Therapeutics, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

182 Active assets in the Multiple Sclerosis (MS) cohort.

Asset / SponsorPhaseRating
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB

View all 50 →

Same molecule, other indications

18f-op-801 is also rated in:

Alzheimer diseaseDormant
CC
Indicative ·
47 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative ·
45 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →